Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Get full access to
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(}function setPanelState(o){dom.root.classList[o?"add":"remove"](,dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

A dose of the Pfizer-BioNTech COVID-19 vaccine at a vaccination site in Vancouver on March 11, 2021.


Canada and other wealthy countries are continuing to stall a five-month-old proposal for a temporary waiver on COVID-19 vaccine patents, sparking criticism that they are defending pharmaceutical companies at the expense of poorer countries.

The proposal, supported by more than 100 countries in the developing world, was again blocked at a meeting of the World Trade Organization in Geneva this week. Further talks are scheduled for next month, but there are few signs that the wealthy countries will give in.

The proposal, originally put forward by South Africa and India last October, would loosen the restrictions on patents for COVID-19 products, including vaccines, so that production can be expanded. The vast majority of vaccinations so far have been in wealthy countries, while most poorer countries have vaccinated few or none of their people.

Story continues below advertisement

Tracking Canada’s COVID-19 vaccine rollout plans: A continuing guide

Coronavirus tracker: How many COVID-19 cases are there in Canada and worldwide? The latest maps and charts

Supporters of the patent waiver have suggested the proposal should at least be allowed to move to the next step of the WTO process, where a draft could be negotiated. The WTO meetings, however, usually operate by consensus, and there was no agreement this week to move to that step.

Canada has repeatedly said it is merely asking questions about the patent waiver proposal, rather than opposing it. But a leading drug-company lobby group, the Pharmaceutical Research and Manufacturers of America, in a letter to the U.S. government this month, publicly named Canada as one of several countries opposing the waiver.

At the WTO meeting this week, South Africa accused the Canadian government of hypocrisy for opposing the patent waiver after introducing its own emergency legislation in March, 2020, to allow it to suspend patent rights and authorize the immediate licensing of vaccines or drugs. The emergency legislation remained in effect for six months, but Ottawa never used it.

In its official response to Canada and other critics of the patent waiver at the WTO meeting, South Africa said they were continually demanding evidence that had already been provided – a “classic tactic to stall matters,” it said.

Youmy Han, press secretary for International Trade Minister Mary Ng, denied Canada is rejecting the waiver proposal. “We are committed to finding consensus-based solutions,” she told The Globe and Mail in an e-mail on Thursday.

“Canada welcomes any further information on these questions, and continues to engage WTO members … in order to identify specific IP-related barriers,” she said.

A coalition of health activists, known as the People’s Vaccine Alliance, held demonstrations in support of the patent waiver on Thursday at the offices of pharmaceutical companies in the United States, South Africa and other countries.

Story continues below advertisement

The alliance, in a statement on Thursday, said the wealthy countries at the WTO are defending the profits of pharmaceutical companies and ignoring the pleas of the developing world. Many people will die as a result, it said.

In a letter to vaccine manufacturers, the alliance said the companies had received billions of dollars in government funding to support their development of the COVID-19 vaccines, yet there are still acute shortages of vaccines and limited sharing of vaccine technology.

Other groups voiced similar concerns after the two-day WTO meeting ended on Thursday. “We are once again disappointed that a small group of countries keeps stalling the process and denying the need to urgently move forward with this landmark waiver on intellectual property during the pandemic,” said Yuanqiong Hu, senior legal and policy adviser for an access campaign at Médecins sans Frontières (Doctors Without Borders).

In Ottawa, the federal New Democrats said the government’s stand at the WTO will damage the global recovery from the pandemic. “If the world does not work together on this effort to vaccinate underdeveloped countries, 30 per cent more people will die and dangerous variants will develop,” said Heather McPherson, the NDP critic for international development.

In a proposal submitted to the WTO this week, Canada and six other countries called on the trade organization to convene discussions with vaccine manufacturers to encourage licensing agreements and technology transfers.

In their proposal, they acknowledged there is an urgent need to promote the rapid and equitable distribution of vaccines. “The scaling up of vaccine production must be a fundamental priority, as no one is safe until everyone is safe,” they said.

Story continues below advertisement

The concept of voluntary technology transfers and licensing deals, dubbed the “Third Way,” has gained growing support in recent weeks, including from the WTO’s new director-general, Ngozi Okonjo-Iweala, a former Nigerian finance minister and current chair of a global vaccine alliance, who has said the issue of vaccine distribution will be a top priority for her. Canada has argued this proposal would provide a broader range of solutions than the patent waiver.

But groups such as MSF have maintained the voluntary measures won’t produce the needed improvements in vaccine access. “These governments know that this will not be sufficient,” Dr. Hu said.

Oxfam’s health policy manager, Anna Marriott, said the WTO meeting this week was “a massive missed opportunity to speed up and scale up the production of lifesaving vaccines worldwide.”

Oxfam has estimated the world’s wealthy countries are together vaccinating their citizens at a rate of one person a second. Yet these countries are “siding with a handful of pharmaceutical corporations in protecting their monopolies against the needs of the majority of developing countries who are struggling to administer a single dose,” Ms. Marriott said in a statement.

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies